EW Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

$87.47  -2.04 (-2.28%)
As of 05/12/2021 16:00:02 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  03/27/2000
Outstanding shares:  621,636,777
Average volume:  2,961,734
Market cap:   $56,195,964,641
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    28176E108
ISIN:        US28176E1082
Sedol:      2567116
Valuation   (See tab for details)
PE ratio:   65.39
PB ratio:   11.95
PS ratio:   12.56
Return on equity:   18.27%
Net income %:   19.02%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy